Triple Therapy Antiviral Combination Seems Promising for COVID-19 in Open-label, Randomized, Phase 2 Trial

Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial – The Lancet

Commentaries: Interferon beta-1b for COVID-19 – The Lancet AND New triple antiviral drug combination shows early promise for treating COVID-19 in phase 2 randomized trial – The Lancet AND A Drug Cocktail Hastens Recovery in Some Coronavirus Patients – The New York Times AND Triple drug therapy helps coronavirus patients recover more quickly, study finds – CNN AND Triple antiviral drug shows early promise in COVID-19 trial – Reuters AND Expert reaction to a study about a phase 2 trial of a triple antiviral drug combination treatment for COVID-19 – Science Media Centre